The iTind™ device is a temporary nitinol implant placed for 5–7 days to remodel prostate tissue, improving urine flow³ without heat, cutting, or permanent implants.

It’s done via outpatient or in-office cystoscopy, using standard urology equipment. The device is placed in a folded configuration and removed after 5–7 days.

The device exerts pressure at 12, 5, and 7 o’clock positions, reshaping the prostatic urethra through ischemic pressure, which remains post-removal.

It depends on the patient and practice preference. In many cases, local anesthesia is sufficient for both procedures, but some providers may opt for conscious sedation. It is considered an outpatient or office-based procedure.^1,2

The radial and longitudinal pressure applied by the device leads to ischemic compression of the prostatic tissue. This creates three longitudinal channels that reshape the prostatic urethra, resulting in improved urinary flow.³

Removal is typically done in the office or outpatient setting. The device is retrieved in one piece, with no fragments left behind.

Yes. While the iTind™ procedure aims for long-term symptom relief (studies demonstrate durability beyond 4 years³), it does not preclude repeat treatment or future interventions, including surgical procedures, if the condition progresses.

No. The entire device is removed after 5–7 days. No stent, implant, scaffold or chemicals remain in the body.

Prospective, multicenter trials with results lasting beyond 4 years show durable symptom relief with rapid return to daily life.^2,3

Studies show preservation of urinary continence and sexual function, including ejaculation, unlike more invasive options.^1,2,6

Temporary urgency, discomfort, dysuria, or hematuria may occur. Rare risks include UTI and urinary retention.

Durability is supported by follow-up data beyond 48 months.³ Many patients remain off medication and do not require retreatment within that time window.^1,3

Based on the AUA guidelines published in 2023, the iTind procedure is best suited for prostates between 25 and 75g without an obstructive median lobe.

Men 50+ with moderate BPH symptoms who want a drug-free, less invasive option and prefer to avoid long-term medication or surgery.

Contraindications for treatment with the iTind procedure include: active urinary tract infection or prostatitis, artificial urinary sphincter or any implant within the urethra, prostate cancer, bladder cancer, bladder atonia, neurogenic bladder disorder, and urinary obstruction due to causes other than BPH, including urethral stricture.⁵

Yes, it may be a viable option for patients who are not surgical candidates but still seek symptom relief, provided their anatomy is suitable and they can tolerate outpatient cystoscopy.

Previous placement of a penile prosthesis is not a contraindication for the iTind procedure.⁵

Olympus provides a reimbursement guide with CPT/HCPCS codes, billing workflows, and place-of-service guidance for office, ASC, or hospital outpatient settings. Coverage may vary by payer, so it's recommended to confirm patient-specific benefits.

Leverage existing cystoscopy tools already in your practice, identify scheduling blocks for the two visits (insertion and removal), train staff on patient education, and coordinate benefits verification with billing teams.

The iTind procedure may be reimbursed when performed in a physician’s office, ASC, or hospital outpatient setting. The specific coding and payment structure may vary depending on medical policy and provider contracts.

Refer to Olympus’s reimbursement guide or contact your Field Reimbursement Manager.

Yes. Olympus provides reimbursement resources including the Field Reimbursement Management Team, the Olympus UNITE Patient Access Program, the reimbursement helpline, and additional resources available here: https://medical.olympusamerica.com/reimbursement-resources.